# Safety, Tolerability and Pharmacokinetic Profile of M108 Monoclonal Antibody in Patients With Advanced Unresectable Solid Tumors in China

> **NCT04894825** · PHASE1 · UNKNOWN · sponsor: **FutureGen Biopharmaceutical (Beijing) Co., Ltd** · enrollment: 152 (estimated)

## Conditions studied

- Advanced Unresectable Solid Tumors

## Interventions

- **DRUG:** M108
- **DRUG:** M108

## Key facts

- **NCT ID:** NCT04894825
- **Lead sponsor:** FutureGen Biopharmaceutical (Beijing) Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-11
- **Primary completion:** 2024-07-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 152 (ESTIMATED)
- **Last updated:** 2023-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04894825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04894825, "Safety, Tolerability and Pharmacokinetic Profile of M108 Monoclonal Antibody in Patients With Advanced Unresectable Solid Tumors in China". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04894825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*